Date: 2015-03-11
Type of information: Distribution agreement
Compound: Foscavir® (foscarnet sodium)
Company: Clinigen (UK) Hospira (USA - IL)
Therapeutic area: Infectious diseases
Type agreement: distribution
Action mechanism:
Disease: HIV/AIDS-related cytomegalovirus infections and herpes
Details: * On March 11, 2015, Clinigen Group announced the extension and renegotiation of the exclusive license and distribution agreement with Hospira for its anti-viral product Foscavir® (foscarnet sodium) in the US. This is expected to be beneficial to both parties. Foscavir® is Clinigen\'s lead product. Foscavir® received FDA approval in May 2012 for the treatment of HIV/AIDS-related cytomegalovirus infections and herpes. In September 2014, the FDA recognized the determined efforts made by Clinigen in providing Foscavir® to patients in the US by awarding Clinigen the first Drug Shortage Assistance Award.
The original distribution agreement with Hospira established in July 2011 was due to expire in May 2017. The new agreement is for five years extending the term to 31 December 2019.
Financial terms:
Latest news:
